• DOI:10.1158/0008-5472.CAN-16-2784
Corpus ID: 4786243

STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy.

@article{Dahal2017STINGAR,
  title={STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy.},
  author={L. N. Dahal and Lang Dou and K. Hussain and R. Liu and Alexander Earley and K. Cox and Salome Murinello and Ian P Tracy and F. Forconi and A. J. Steele and P. Duriez and D. Gomez-Nicola and J. Teeling and M. Glennie and M. Cragg and S. Beers},
  journal={Cancer research},
  year={2017},
  volume={77 13},
  pages={
          3619-3631
        }
}

L. N. Dahal, Lang Dou, +13 authors S. Beers

Published 2017

Biology, Medicine

Cancer research

Tumors routinely attract and co-opt macrophages to promote their growth, angiogenesis, and metastasis. Macrophages are also the key effector cell for mAb therapies. Here we report that the tumor microenvironment creates an immunosuppressive signature on tumor-associated macrophages (TAM), which favors expression of inhibitory rather than activating Fcγ receptors (FcγR), thereby limiting the efficacy of mAb immunotherapy. We assessed a panel of TLR and STING agonists (a) for their ability to… CONTINUE READING

View PDF

Save to Library

Create Alert

Cite

Launch Research Feed